Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 39116016 · doi:10.1080/10408398.2024.2387324
What was done
A systematic review and random-effects meta-analysis of randomized controlled trials searched four databases (PubMed, Embase, Cochrane, Web of Science) to assess the effects of oral NMN supplementation on fasting glucose, triglycerides, total cholesterol, LDL-C, HDL-C, and blood NAD levels in adults. Two reviewers independently performed study selection, data extraction, and risk-of-bias assessment using the RoB 2 tool.
What was found
Across 12 studies encompassing 513 participants, random-effects meta-analyses showed an overall significant effect of NMN supplementation in elevating blood NAD levels. However, most clinically relevant metabolic outcomes showed no statistically significant differences between the NMN and control groups. The abstract reports no numerical effect sizes, p-values, or confidence intervals.
Why it matters
Despite widespread interest in NMN supplementation for metabolic enhancement, current trial evidence does not support meaningful improvements in glycemic or lipid profiles, indicating that claimed metabolic benefits may be exaggerated.
Limits
The abstract provides no point estimates, effect sizes, or confidence intervals. Methodological quality across the primary studies was poor, with 7 trials showing some concerns and 5 trials showing high risk of bias. The total evidence base is small, comprising only 513 participants across 12 trials.
Cited by
- supports Clinical studies demonstrate that oral NMN supplements increase metabolite levels in human blood.